{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:24:00Z","timestamp":1787639040004,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-related myoclonus and epileptic seizures are neurological adverse events that may cause trauma, impaired consciousness, hospitalization, treatment interruption, and life-threatening outcomes. In practice, these events may be difficult to distinguish from neurological diseases, metabolic abnormalities, disease progression, or complications of comorbidities and polypharmacy. Research has focused on individual drugs, case reports, or specific populations, leaving the risk-drug spectrum, sex-related reporting patterns, and onset characteristics insufficiently characterized. Systematic evaluation of these features is important for early identification, optimized monitoring, and individualized risk management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports from 2004Q1 to 2025Q4 were analyzed. Drug names were standardized using RxNorm, and adverse events were identified using MedDRA 27.1 preferred terms. Primary suspect drugs were evaluated by reporting odds ratio (ROR)-based disproportionality analysis. Sex-stratified analysis, ATC classification, time-to-onset (TTO) analysis, Weibull modeling, and cross-database validation using CVARD were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Reports were concentrated in North America, Europe, and East Asia, with female predominance and most patients aged 18\u201365 years. A total of 165 myoclonus-related and 235 epileptic seizure-related risk drugs were identified. Nervous system agents predominated, while antiinfectives, antineoplastic and immunomodulating agents, metabolic drugs, and cardiovascular agents also contributed. Bupropion had the highest report count (1,412; 265 myoclonus and 1,147 epileptic seizure reports), followed by tramadol (829). For myoclonus, gabapentin showed strong signals in males (ROR = 23.31, 95% CI: 20.95\u201325.95) and females (ROR = 18.06, 95% CI: 16.24\u201320.08), whereas tranexamic acid showed the strongest male signal (ROR = 128.41, 95% CI: 98.29\u2013167.75). For epileptic seizures, bupropion showed signals in males (ROR = 18.08, 95% CI: 16.21\u201320.17) and females (ROR = 20.21, 95% CI: 18.70\u201321.85), with tramadol signals in both sexes. Drugs exhibited early-failure Weibull patterns (\u03b2 &amp;lt; 1). Median TTOs were 16.5 days for pregabalin-related myoclonus and 31.0 days for tramadol-related seizures, but 214.0 days for lamotrigine and 387.0 days for interferon beta-1a. CVARD identified 498 myoclonus-related and 940 seizure-related drugs and reproduced core signals, including clozapine, gabapentin, baclofen, pregabalin, sertraline, bupropion, quetiapine, and olanzapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating signal detection, sex-stratified analysis, TTO modeling, and cross-database validation identified core risk drugs and monitoring windows, supporting earlier recognition and individualized management of drug-related neurological adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1907007","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:36:03Z","timestamp":1787636163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-specific pharmacovigilance signals and time-to-onset patterns of drug-related myoclonus and epileptic seizures: a real-world pharmacovigilance analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Fu","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yuan","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxi","family":"Yao","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shang","sequence":"additional","affiliation":[{"name":"School of Clinical Chinese Medicine, Gansu University of Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","volume-title":"Bupropion Toxicity: Statpearls","author":"Alberter","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ph15030298","article-title":"A Sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases","volume":"15","author":"Brabete","year":"2022","journal-title":"Pharm. Basel, Switz."},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.clinthera.2025.12.013","article-title":"Safety assessment of budesonide\/formoterol: real-world pharmacovigilance analysis using the FAERS, JADER, and CVAR databases","volume":"48","author":"Chen","year":"2026","journal-title":"Clin. Therapeutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","article-title":"Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice","volume":"14","author":"Chincholkar","year":"2020","journal-title":"Br. Journal Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/TCRM.S262843","article-title":"Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists","volume":"16","author":"Coluzzi","year":"2020","journal-title":"Ther. Clinical Risk Management"},{"key":"B6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jocn.2018.09.019","article-title":"Gabapentin or pregabalin induced myoclonus: a case series and literature review","volume":"61","author":"Desai","year":"2019","journal-title":"J Clin Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.ebr.2024.100679","article-title":"Do psychotropic drugs cause seizures?","volume":"27","author":"Gopaul","year":"2024","journal-title":"Epilepsy and Behavior Reports"},{"key":"B8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40266-024-01117-w","article-title":"Central nervous system medications: pharmacokinetic and pharmacodynamic considerations for older adults","volume":"41","author":"Gronich","year":"2024","journal-title":"Drugs and Aging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2589","DOI":"10.1002\/brb3.2589","article-title":"The burden of epilepsy and unmet need in people with focal seizures","volume":"12","author":"Ioannou","year":"2022","journal-title":"Brain Behavior"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00415-016-8357-z","article-title":"The clinical heterogeneity of drug-induced myoclonus: an illustrated review","volume":"264","author":"Janssen","year":"2017","journal-title":"J. Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/ph15101254","article-title":"Investigation of the mechanisms of tramadol-induced seizures in overdose in the rat","volume":"15","author":"Lagard","year":"2022","journal-title":"Pharm. Basel, Switz."},{"key":"B14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.clinph.2023.10.007","article-title":"Rethinking the neurophysiological concept of cortical myoclonus","volume":"156","author":"Latorre","year":"2023","journal-title":"Clin Neurophysiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/mdc3.14306","article-title":"Diagnostic utility of clinical neurophysiology in jerky movement disorders: a review from the MDS clinical neurophysiology study group","volume":"12","author":"Latorre","year":"","journal-title":"Mov. Disorders Clinical Practice"},{"key":"B16","doi-asserted-by":"publisher","first-page":"107216","DOI":"10.1016\/j.parkreldis.2024.107216","article-title":"IAPRD new consensus classification of myoclonus","volume":"132","author":"Latorre","year":"","journal-title":"Park. and Related Disorders"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.24558","article-title":"Tranexamic acid-associated seizures: causes and treatment","volume":"79","author":"Lecker","year":"2016","journal-title":"Ann. Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"110722","DOI":"10.1016\/j.yebeh.2025.110722","article-title":"Psychiatric disorders associated with newer antiseizure medications: a real-world disproportionality analysis of FDA adverse event reporting system","volume":"172","author":"Li","year":"2025","journal-title":"Epilepsy and Behavior"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111417","DOI":"10.1016\/j.jclinane.2024.111417","article-title":"Kidney disease in trials of perioperative tranexamic acid","volume":"94","author":"Liu","year":"2024","journal-title":"J. Clinical Anesthesia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1571577230","DOI":"10.1177\/20420986221125006","article-title":"Pharmacovigilance: reporting requirements throughout a product's lifecycle","volume":"13","author":"Lucas","year":"2022","journal-title":"Ther. Advances Drug Safety"},{"key":"B21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/10408444.2019.1694861","article-title":"Tramadol and the occurrence of seizures: a systematic review and meta-analysis","volume":"49","author":"Nakhaee","year":"2019","journal-title":"Crit. Reviews Toxicology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e55551","DOI":"10.1136\/bmjopen-2021-055551","article-title":"Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions","volume":"12","author":"Osanlou","year":"2022","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000551382","article-title":"The global macroeconomic burden of neurological disorders","author":"Ouyang","year":"2026","journal-title":"Neuroepidemiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1825269","DOI":"10.3389\/fphar.2026.1825269","article-title":"Immune checkpoint inhibitors and myocarditis-myositis-myasthenia gravis overlap: a FAERS pharmacovigilance study with time-to-onset characterization","volume":"17","author":"Pacaci","year":"2026","journal-title":"Front. Pharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/epi.17240","article-title":"International league against epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Riney","year":"2022","journal-title":"Epilepsia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/medicina61010131","article-title":"Drug-induced myoclonus: a systematic review","volume":"61","author":"Rissardo","year":"2025","journal-title":"Med. Kaunas. Lith."},{"key":"B27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/epi4.12917","article-title":"Myoclonus: differential diagnosis and current management","volume":"9","author":"Riva","year":"2024","journal-title":"Epilepsia Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-0447.1997.tb09933.x","article-title":"Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors","volume":"96","author":"Spigset","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1551","DOI":"10.1016\/j.sapharm.2026.05.009","article-title":"Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65 years: based on the FDA adverse event reporting system (FAERS)","volume":"22","author":"Wang","year":"2026","journal-title":"Res Social Adm Pharm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.seizure.2020.08.012","article-title":"Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations","volume":"81","author":"Wanleenuwat","year":"2020","journal-title":"Seizure"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e214270","DOI":"10.1212\/WNL.0000000000214270","article-title":"Risk of seizure associated with concomitant use of tramadol and antidepressants in older nursing home residents","volume":"105","author":"Wei","year":"2025","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e340357","DOI":"10.1371\/journal.pone.0340357","article-title":"Suicide adverse events associated with zopiclone and eszopiclone: a pharmacovigilance analysis based on FAERS, JADER and CVARD","volume":"21","author":"Xu","year":"2026","journal-title":"PloS One."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1111\/epi.18595","article-title":"Suspected induction of epileptic negative myoclonus after lacosamide initiation","volume":"66","author":"Yamamoto","year":"2025","journal-title":"Epilepsia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"108693","DOI":"10.1016\/j.yebeh.2022.108693","article-title":"Movement disorders associated with antiseizure medications: a systematic review","volume":"131","author":"Zhou","year":"2022","journal-title":"Epilepsy and Behavior"},{"key":"B35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/genes15020171","article-title":"Progressive myoclonus epilepsy: a scoping review of diagnostic, phenotypic and therapeutic advances","volume":"15","author":"Zimmern","year":"2024","journal-title":"Genes"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e335449","DOI":"10.1371\/journal.pone.0335449","article-title":"Drug-induced movement disorder: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024","volume":"20","author":"Zou","year":"2025","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol. Sex Differences."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1907007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:36:05Z","timestamp":1787636165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1907007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1907007"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1907007","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1907007"}}